# Pfizer Enters in Vivo CAR-T Field with $2.6 Billion Deal for Starna Therapeutics Programs

Pfizer has entered the in vivo CAR-T space through a $2.6 billion licensing agreement with China-based Starna Therapeutics. The deal covers three preclinical candidates.

The agreement gives Pfizer rights to develop and commercialize Starna's in vivo CAR-T programs. These therapies are designed to generate CAR-T cells directly inside the patient's body, eliminating the need to extract and modify a patient's own cells in a laboratory.

Starna will receive an upfront payment and is eligible for milestone payments totaling $2.6 billion across the three programs. All three candidates remain in preclinical development.

**Why this matters for life sciences**

In vivo CAR-T represents a potential shift in cell therapy manufacturing. Current CAR-T treatments require a multi-week process of collecting a patient's T cells, genetically engineering them in a specialized facility, and reinfusing them. In vivo approaches aim to deliver the genetic instructions for CAR expression directly into the patient's body, using lipid nanoparticles or viral vectors. If successful, this could reduce manufacturing costs, shorten treatment timelines, and expand patient access to CAR-T therapies. Pfizer's entry, alongside other major pharmaceutical companies already investing in this technology, signals growing industry confidence that in vivo delivery may overcome the logistical and scalability challenges that have limited CAR-T adoption to specialized cancer centers.

Source: [Pfizer enters in vivo CAR-T space via 3-program, $2.6B deal with China’s Starna](https://www.fiercebiotech.com/biotech/pfizer-enters-vivo-car-t-space-3-program-26b-deal-chinas-starna)